Indeed, in addition to significantly reducing the serum levels of IL-6 and C-reactive protein (CRP) (77, 112), ruxolitinib could influence the regulation of several inflammatory cytokines (including IL-2, IL-5, and IL-10) (36, 113), and consequently reduce hyperferritinemia. Here, CRP is linked to isolated hyperferritinemia.